 LA JOLLA, Calif., March 25, 2021 PRNewswire -- Avidity Biosciences, Inc. Nasdaq: RNA, a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates AOCsTM, today announced that management will be participating in the following virtual investor conferences: Guggenheim Healthcare TalksGenomic Medicines and Rare Disease Day Conference Thursday, April 1 st, 2021, 6:00 am PDT Panel on Duchenne Muscular Dystrophy DMD Participants include: Arthur Levin, PhD, Chief Scientific Officer, Avidity Biosciences Michael Binks, MD, Vice President of Clinical Research, Pfizer Louise Rodino-Klapac, PhD, Chief Scientific Officer, Sarepta Therapeutics Carl Morris, PhD, Chief Scientific Officer, Solid Biosciences Sam Wadsworth, Chief Scientific Officer, Ultragenyx Pharmaceutical 2021 Virtual Wells Fargo Biotech Corporate Access Day Tuesday, April 6 th, 2021 Avidity management participation in investor 1x1 meetings 20th Annual Needham Virtual Healthcare Conference Monday, April 12 th, 2021, 12:45pm PDT Webcast presentation Live webcasts of the Guggenheim panel and Needham presentation will be available on the Investors section of Aviditys website and a replay of both events archived on the site. 